483
Views
10
CrossRef citations to date
0
Altmetric
Review

Roseomonas species infections in humans: a systematic review

ORCID Icon, &
Pages 226-236 | Received 24 Mar 2020, Accepted 17 Jun 2020, Published online: 03 Jul 2020
 

Abstract

Roseomonas species have been recognized to cause infections in immunocompromised individuals. The purpose of this study was to systemically review all published cases of Roseomonas infections in humans and describe the epidemiology, microbiology, antimicrobial susceptibility, treatment and outcomes of these infections in humans. We performed a systematic review of PubMed (through 20th Octrober 2019) for studies providing epidemiological, clinical, microbiological as well as treatment data and outcomes of Roseomonas species infections. A total of 37 studies, containing data of 99 patients, were included in the analysis. The most common Roseomonas infections were those of the bloodstream in 74.7% (74 patients), musculoskeletal infections in 8.1% (8 patients), skin and soft tissue infections (SSTIs) and peritoneal dialysis-associated peritonitis in 6.1% (6 patients) each. Epidemiology of these infections differed, with bacteremias being more prevalent in patients with malignancy and central venous lines, musculoskeletal infections being more prevalent after orthopedic surgery, and SSTIs occurring without any reported underlying cause. Resistance to beta-lactams was very high with penicillin, piperacillin/tazobactam resistance and cephalosporin resistance at 96.6%, 90.7% and 77.8% respectively, while quinolone resistance was 9.1%. Quinolones, carbapenems and cephalosporins are the most common agents used for treatment, irrespectively of the infection site. Overall mortality was 3% (3 patients), with the mortality attributed to Roseomonas being at 1% (1 patient).

Disclosure statement

The authors report no conflict of interest.

Additional information

Notes on contributors

Petros Ioannou

Petros Ioannou is a registrar in the Internal Medicine Department at the University Hospital of Heraklion. He has been trained in the University Hospital of Heraklion in Crete, In Boston Medical Center in USA, in the McGill University Hospital Center in Canada, in the Nuffield Orthopaedic Centre in Oxford, UK, in the University College of London Hospital in London, UK and in the Groote Schuur Hospital in Cape Town, South Africa.

Vasiliki Mavrikaki

Vasiliki Mavrikaki is a chief resident in the Internal Medicine Department at the University Hospital of Heraklion in Crete, Greece.

Diamantis P Kofteridis

Diamantis P Kofteridis is an associate professor in the Internal Medicine Department and chief of the COVID-19 Department at the University Hospital of Heraklion in Greece. He was trained in the University Hospital of Heraklion in Greece, in MD Anderson in Texas, USA and in the University of Dundee in UK.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.